of short peripheral catheters fail before the end of treatment in a large multicentre study.
CATHEVAL project, France · PLOS ONE 2016The two-minute midline.
Standard over-the-needle insertion with midline performance.
M/29 Bullpup™ is the mini-midline any IV nurse can place: about two minutes at the bedside, up to 29 days of peripheral IV access. For nurses and physicians: fewer re-sites and needle sticks, no guidewire, no specialist team, no waiting list.
- Up to 29 days
- ~2 minute insertion
- 18–22G · 78–98 mm
- 325 PSI rated
- CE · EU MDR
~2minto place, at the bedside
CE marked under EU MDR Class IIa
ISO 13485 certified manufacturing
Peer-reviewed data Israel 2025 · Poland 2026
Patented worldwide proprietary design
In daily use in hospitals across Europe
The 4-to-29-day gap
Most IV patients stay longer than a cannula lasts, and far shorter than a PICC is meant for
Short cannulas often fail before therapy ends. Guidewire midlines and PICCs need trained teams, equipment and time, so most ward patients never get one. The M/29 Bullpup is built for the patients in between.
One patient, four weeks of IV therapy. How many needle sticks?
= needle stick / insertionShort cannulaFails or is re-sited every 2–4 days
8+
M/29 BullpupOne insertion at the bedside, by any IV nurse
Up to 29 days
1
Guidewire midlineNeeds a vascular-access team, often a wait
wait
1 + wait
PICCCentral line for weeks to months, specialist placement
weeks to months
1 central
re-insertions are common for patients staying 10–15 days, according to ward nursing supervisors.
Internal medicine nursing supervisor, Spain · nursing management journal, 2019guidewires, dilators or scalpels. M/29 goes in like the cannula your nurses place every day.
M/29 Instructions for Use“You can’t insert a midline on everyone.”
How it works
Midline length. Cannula technique.
- 1
Puncture like a standard IV
Familiar over-the-needle approach. The notched needle shows flashback instantly, and the tip is visible under ultrasound.
- 2
Advance without touching the catheter
The handle advances the 8.5–10 cm polyurethane catheter off the needle, keeping the catheter itself untouched.
- 3
Needle locks safely, line stays up to 29 days
The safety guard protects the needle tip on withdrawal. Secure, connect an extension set and use for up to 29 days.
Clinical evidence
Independent hospitals, published results
Data from university hospitals in Poland, Israel and the Czech Republic, where M/29 is used in routine care.
2.7%removed for occlusion, vs 21.8% with a guidewire midlineWarsaw University Clinical Centre · 2026
62.7%stayed in place until the end of therapy, vs 44.5%Warsaw University Clinical Centre · 2026
13complications per 1,000 catheter-days, not counting dislodgement*. Vasopressors given safely in 22 patientsRambam Health Care Campus · 2025
130 saverage insertion time, at the bedsideRambam Health Care Campus · 2025
21%of patients went home with the line for continued IV therapyRambam Health Care Campus · 2025
* Dislodgement was recorded separately: 53 of 128 catheters (41%). Phlebitis 8, occlusion 5, infiltration 1, suspected infection 1 (negative cultures).
For distributors
Why partners add M/29 to their portfolio
Same customers, new revenue
It sells to the people you already visit: IV therapy, anaesthesia and ICU, and the nurses on internal medicine wards. It sits right next to your cannulas, dressings and connectors.
A category with room to grow
Over-the-needle mini-midlines are still new in most hospitals. M/29 is priced between a cannula and a guidewire midline, so it opens budgets that neither device reaches.
Tender-ready from day one
EU MDR certificate, ISO 13485, declarations of conformity, technical data sheets and multilingual IFU. You get everything needed for local registration and tender files.
A repeat-volume consumable
Every admitted patient on IV therapy for more than a few days is a candidate. Usage spreads ward by ward once nurses see fewer re-sites.
Training in minutes, not weeks
Any trained IV inserter can place it. A short in-service on the ward replaces vascular-access team certification.
A manufacturer behind you
Demo units, clinical decks, an insertion guide, patient follow-up forms and one-on-one online training for your team.
The proven path
How our fastest-growing markets were built
In Central Europe, specialist distributors took M/29 from a few trial wards to hospital tenders, with growth every year. We follow the same four steps with every new partner.
- 01
Pilot
2–3 wards with a clinical champion. We supply demo units and run in-service training with your specialists.
Months 1–3 - 02
Prove
Track dwell time and complications on a simple follow-up form, then turn the results into a local case.
Months 3–6 - 03
List
Hospital formulary and tender specifications, built on your reference wards.
Months 6–12 - 04
Scale
More hospitals, ICU step-down and home IV therapy. Then regional and national tenders.
Year 2 onwards
Territories
We are appointing partners now
We work with one specialist partner per territory, with clear targets and full support. Priority regions for 2027:
- France
- Romania & Moldova
- Bulgaria
- Serbia
- Croatia
- Slovenia
- Bosnia & Herzegovina
- North Macedonia
- Albania & Kosovo
- Lithuania
- Latvia
- Estonia
- Hungary
Other markets: talk to us. Established partners serve Poland, the Czech Republic and Slovakia, Spain, Scandinavia and the Netherlands.
Explore the partner programReady to bring M/29 to your hospitals?
Request samples, the clinical deck and pricing for your territory.